ScholarLens Back to search
2003•Applied Journal of General PracticeRequires access

Clinical effects of As 2O 3 in previously untreated patients of acute promyelocytic leukemia

He-Sheng He

Open publisher page 0 citations

Abstract

Objective To observe the clinical effects of arsenic trioxide (As 2O 3) in acute promyelocytic leukemia(APL) patients. Methods As 2O 3 was given to twenty-four previously untreated APL patients ,and DA or HA regimens were used as maintance treatment. Results Complete remission rate(CR) was 83.3%. The longest survival time among twenty follow-up surrey patients was five years .There were 9 cases with central nervous system leukemia (CNSL) (37.5%). Conclusion The CR rate was high,the relapse was low , the side effect was mild ,and no cross drug-resistance with all-trans retinoic acid(ATRT). As 2O 3 was a new promising differentiation-inducing agent for APL.

About this research paper

What this paper is about

Objective To observe the clinical effects of arsenic trioxide (As 2O 3) in acute promyelocytic leukemia(APL) patients. Methods As 2O 3 was given to twenty-four previously untreated APL patients ,and DA or HA regimens were used as maintance treatment. Results Complete remission rate(CR) was 83.3%. The longest survival time among twenty follow-up surrey patients was five years .There were 9 cases with central nervous system leukemia (CNSL) (37.5%). Conclusion The CR rate was high,the relapse was low , the side effect was mild ,and no cross drug-resistance with all-trans retinoic acid(ATRT). As 2O 3 was a new promising differentiation-inducing agent for APL.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To observe the clinical effects of arsenic trioxide (As 2O 3) in acute promyelocytic leukemia(APL) patients. Methods As 2O 3 was given to twenty-four previously untreated APL patients ,and DA or HA regimens were used as maintance treatment. Results Complete remission rate(CR) was 83.3%. The longest survival time among twenty follow-up surrey patients was five years .There were 9 cases with central nervous system leukemia (CNSL) (37.5%). Conclusion The CR rate was high,the relapse was low , the side effect was mild ,and no cross drug-resistance with all-trans retinoic acid(ATRT). As 2O 3 was a new promising differentiation-inducing agent for APL.

Key concepts: Arsenic trioxide, Acute promyelocytic leukemia, Medicine, Complete remission, Internal medicine, Retinoic acid, Leukemia, Gastroenterology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Clinical effects of As 2O 3 in previously untreated patients of acute promyelocytic leukemia — Research Paper | ScholarLens